Life Sciences 4.0

Posted by

“Embracing Life Sciences 4.0 is both a global urgent need and an opportunity. If companies leverage technology to create platform interfaces and combine their proprietary data with those from other health stakeholders, they can position themselves as powerful leaders and capture sustainable future value” – EY presents latest edition of “Progressions” series.

Life sciences companies have already started to respond to this new demand-driven environment by shifting their business models away from blockbuster and specialty products and toward outcomes-based business models. They must now consider how and when to participate in emerging care platforms that seamlessly collect, combine and share a variety of health data in real time. This will involve the formation of agile, and often short-term, partnerships and collaborations. We call the data-driven, platform-based business models that emerge from such efforts Life Sciences 4.0.

Embracing Life Sciences 4.0 is both an urgent need and a blossoming opportunity that has yet to be realized. If life sciences companies can leverage platforms to combine their proprietary data with environmental, behavioral and financial insights, they can position themselves to capture maximum future value.

In the retail and transportation industries, where data exchange is fast and easy, companies have eliminated long-standing inefficiencies and created benefits for themselves and their customers. Life Sciences 4.0, likewise, can help medtechs and biopharmas unlock and capture value, allowing companies to co-create new solutions that drive improved health outcomes and preserve, or even improve, their position in a rapidly changing health ecosystem.

To seize the upside of disruption in this transformative age, executives should ask themselves the following questions:

  • How will your organization transform its business model to create shared value focused on personalized outcomes and fueled by unlocking the power of data?
  • How will your organization build new capabilities organically, by acquisition or by flexible partnerships?
  • How will your organization ultimately secure value through platform-based businesses?




Click here to download the full EY’s report “Life Sciences 4.0: Securing value through data-driven platforms”.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s